Category Archives: TRIPS plus

The expanding universe of IP

Source: The Hindu Granting data exclusivity for clinical trials would undermine access to medicines April 26 is World Intellectual Property (IP) day. Over the years, global IP standards have steadily expanded beyond World Trade Organisation (WTO) requirements, thanks to free … Continue reading

Posted in Data Exclusivity, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

TPP May Be Dead but Big Pharma’s Still Getting Away with Murder

By: Vijay Das |Source: Telesur For every trade advancement in the name of improving public health and access to essential medicines, Big Pharma counters. The Trans-Pacific Partnership may officially be dead yet a looming free trade battle remains in the … Continue reading

Posted in Evergreening, TPP, Uncategorized | Leave a comment

Switzerland wants stricter intellectual property rules in India that could harm generic drug makers

By Jyotsna Singh, Scroll | March 23, 2017 Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

Study & video released about the impact of the Mercosur/EU FTA on access to medicines in Brazil

This week (March 20-24, 2017) negotiators of the European Union and Mercosur meet once again to move forward with the negotiation of a Free Trade Agreement (FTA). This FTA could have a great impact not only on trade, but in people’s rights, including … Continue reading

Posted in EU-Mercosur FTA under FTA, TRIPS plus, Uncategorized | Leave a comment

European FTA pushes for tougher IPR rules under ongoing trade talks with India

Switzerland proposed that India agree to broader patentable principles, as per a leaked note on the proposed Intellectual Property Rights chapter of the talks   The leaked note followed a telephone conversation commerce minister Sitharaman and Swiss minister for economic … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, IPR, Patent, Uncategorized | Leave a comment

India–EFTA trade talks may make medicines more expensive

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’   Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment